Citations

Abstract Background Although a rhythm control strategy is associated with an overall better prognosis in atrial fibrillation (AF), current guidelines suggest that only highly selected asymptomatic patients may be considered candidates for AF catheter ablation. Therefore, this study aimed to evaluate the association between symptom status and clinical outcomes in patients with AF. Methods A comprehensive search of Medline, the Cochrane Library, and Scopus was conducted up until September 30, 2024. Study selection, data extraction, and quality assessment were performed independently by three reviewers. Random-effects meta-analyses were used to pool the evidence. Results A total of 36 studies, comprising 217,850 participants, were included. Frequentist analysis revealed no significant difference between symptomatic and asymptomatic AF patients in terms of all-cause mortality [hazard ratio (HR) = 0.97, 95% confidence interval (CI)= (0.80, 1.17)], cardiovascular mortality (HR= 1.04, 95% CI= [0.72, 1.49]), thromboembolism (HR= 1.06, 95% CI= [0.87, 1.28]), stroke (HR= 1.06, 95% CI= [0.84, 1.34]), hospitalization (HR= 1.34, 95% CI= [0.89, 2.02]), and myocardial infarction (HR= 0.98, 95% CI= [0.70, 1.36]). However, symptomatic patients exhibited a 33% increased risk of new-onset heart failure (HR= 1.33, 95% CI= [1.19, 1.49]) and a 30% reduced risk of progression to permanent AF (HR= 0.70, 95% CI= [0.54, 0.89]). Bayesian analysis produced similar results, although the association between symptom status and new-onset heart failure was not statistically significant [HR = 1.27, 95% credible interval (CrI)= (0.76, 1.93); Bayes factor (BF10)= 1.2]. Symptomatic patients had higher odds of receiving antiarrhythmic drugs (odds ratio [OR]= 1.64, 95% CI= [1.33, 2.03]) and ablation therapy (OR= 1.47, 95% CI= [1.06, 2.05]) compared to their asymptomatic counterparts. Conclusions The risk of major clinical outcomes does not significantly differ between AF patients with and without symptoms. However, asymptomatic patients have a higher risk of progressing to permanent AF.

Abstract Background Optimal treatment for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma remains unclear due to limited head-to-head comparisons among chemotherapy and chemoradiation regimens. This network meta-analysis aimed to determine the relative efficacy of available multimodality treatment regimens in these patients. Methods MEDLINE, EMBASE, Scopus, Web of Science, and CENTRAL were searched till September 20, 2024. Phase 3 randomized trials evaluating perioperative/neoadjuvant systemic therapy ± radiation in resectable gastric/GEJ adenocarcinoma were included. Primary outcomes were disease-free survival (DFS) and overall survival (OS). Frequentist network meta-analysis was conducted to compare hazard ratios (HRs) and 95% confidence intervals (CIs). Results Fifteen trials (8072 patients) were analyzed. pFLOT (perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel) ranked highest for DFS in the overall population (P-score 91%), achieving significant improvements compared to surgery alone (HR 0.48, 95% CI, 0.38-0.60) and nCROSS (neoadjuvant paclitaxel, carboplatin, and radiotherapy) (0.67, 0.56-0.81). For OS, nPLF + nCRT(EP) (neoadjuvant cisplatin, leucovorin, and fluorouracil for induction, followed by etoposide, cisplatin, and radiotherapy) (P-score 90%) and pFLOT (P-score 87%) were the top regimens. pFLOT significantly outperformed surgery alone (0.57, 0.45-0.72) and nCROSS (0.73, 0.60-0.89). Based on the limited data available, adding neoadjuvant chemoradiation to pFLOT provided no additional OS (1.14, 0.76-1.72) or DFS (1.22, 0.83-1.82) benefit. Similarly, adding pembrolizumab to perioperative chemotherapy (cisplatin and fluorouracil/capecitabine) was not superior to pFLOT (DFS: 1.10, 0.71-1.69; OS: 1.09, 0.69-1.72). Conclusions pFLOT demonstrated superior efficacy in resectable gastric/GEJ adenocarcinoma, outperforming surgery alone, nCROSS, and alternative perioperative regimens. The additive role of immunotherapy requires further investigation to optimize patient selection and outcomes.

Abstract Cortico‐cortical evoked potentials (CCEPs) are an active electrophysiological technique used during intracranial electroencephalography to evaluate the effective connectivity and influence of therapeutic stimulation between distinct cortical regions and pinpoint epileptogenic zones (EZs) in patients with epilepsy. Various methodologies have been implemented to analyze CCEPs and characterize the epileptogenic networks for EZ localization. Despite its promise, their interpretation remains challenging due to the large volumes of spatially and temporally complex data generated. Early studies focused largely on qualitative descriptors and predefined, semi‐quantitative features such as waveform morphology and peak latencies. However, these methods are limited by the significant heterogeneity in CCEP waveform conformations across patients and cortical regions. The specific technique used for extraction of features, such as the spectral band power and root mean squared values, remains open to empirical refinement, as does choice of appropriate latency windows, with no consensus reached regarding the optimal approach. Graph theoretical metrics such as degree centrality, betweenness centrality, and clustering coefficients can provide a rich representation of epileptogenic network connectivity. However, these metrics are often abstract and difficult to interpret in a clinical setting or to the non‐expert, and their neuroscientific substrates remains poorly understood. The lack of standardization in stimulation protocol and data‐processing pipelines has further contributed to inconsistency in reported findings. Emerging machine learning approaches have been increasingly applied to CCEP data, offering a more data‐driven and potentially generalizable way to identify electrophysiological biomarkers of the epileptogenic effective connectivity. In this article, we discuss qualitative, quantitative, and spectral features; network‐analytical metrics; and more recently, data driven methodologies aimed at improving the interpretability and clinical utility of CCEP data.

BACKGROUND AND OBJECTIVES: Dural arteriovenous fistula (DAVF) is characterized by an abnormal vascular connection located within the dura mater. Stereotactic radiosurgery (SRS) offers favorable outcomes for DAVF, with high obliteration rates and low adverse effects. Although short- to mid-term SRS outcomes for DAVFs and long-term outcomes for arteriovenous malformations have been well documented, the long-term outcomes of SRS for DAVF remain unclear. The aim of this study was to elucidate the late radiation-induced complications (LRICs) of SRS for DAVF based on our long-term observational data. Especially, chronic encapsulated hematoma (CEH), which is defined as an organized intraparenchymal hematoma surrounded by a fibrous capsule, was highlighted as a subtype of LRICs. METHODS: We enrolled 30 consecutive patients with 32 DAVFs who underwent SRS at our institution between 1998 and 2017. Cumulative DAVF obliteration and LRICs rates and associated risk factors were analyzed using the Kaplan-Meier method. Post-SRS signal changes were defined as edematous lesions with high T2 signal intensity that appeared after SRS. RESULTS: The median observation period after the SRS was 99 months. Two asymptomatic CEHs occurred in our cohort and were treated conservatively. The cumulative rates for LRICs after SRS were 5.3% at 8 years and 11.1% at 10 years. Post-SRS signal changes were significantly associated with the occurrence of CEH (25.0% vs 0.0% at 8 years; P = .005; log-rank test). CONCLUSION: Although SRS is effective in treating DAVFs, it poses a risk for LRICs. Post-SRS signal changes may be useful predictors of LRIC occurrence.

Objective: Four hypertension-mediated left ventricular hypertrophy (LVH) phenotypes have been reported using cardiac magnetic resonance (CMR): normal LV, LV remodelling, eccentric and concentric LVH, with varying prognostic implications. The electrocardiogram (ECG) is routinely used to detect LVH; however, its capacity to differentiate between LVH phenotypes is unknown. This study aimed to classify hypertension-mediated LVH from the ECG using machine learning and test for associations of ECG-predicted phenotypes with incident cardiovascular outcomes. Methods: ECG biomarkers were extracted from the 12-lead ECG of 20 439 hypertensive patients in UK Biobank (UKB). Classification models integrating ECG and clinical variables were built using logistic regression, support vector machine (SVM), and random forest. The models were trained in 80% of the participants, and the remaining 20% formed the test set. External validation was sought in 877 hypertensive participants from the Study of Health in Pomerania (SHIP). In the UKB test set, we tested for associations between ECG-predicted LVH phenotypes and incident major adverse cardiovascular events (MACE) and heart failure. Results: Among UKB participants 19 408 had normal LV, 758 LV remodelling, 181 eccentric and 92 concentric LVH. Classification performance of the three models was comparable in UKB. SVM (accuracy 0.79, sensitivity 0.59, specificity 0.87, AUC 0.69) was taken forward for external validation with similar results in SHIP. There was superior prediction of eccentric LVH in both cohorts. In the UKB test set, ECG-predicted eccentric LVH was associated with heart failure (hazard ratio 3.42, 95% CI 1.06–9.86). Conclusion: ECG-based ML classifiers represent a potentially accessible screening strategy for the early detection of hypertension-mediated LVH phenotypes.

Erythema elevatum diutinum is a distinct and rare form of chronic, recurrent leukocytoclastic vasculitis that typically presents with firm, smooth erythematous to violaceous papules or nodules symmetrically distributed over the extensor surfaces. Herein, we report an unusual case of erythema elevatum diutinum in a 32-year-old female who presented with a several-year history of chronic recurrent palpable purpura prior to the development of classic nodular lesions. This presentation facilitated a timely diagnosis and highlighted the histopathologic progression of the disease broadening the clinical spectrum of erythema elevatum diutinum.

AbstractObjectivePrevious studies synthesizing published data on nasal septal perforation (NSP) repair outcomes have cited the lack of standardization in evaluation and data reporting. The heterogeneity of this literature base limits the quality of available evidence and precludes intercomparison. The aim of this study is to quantitatively characterize trends in NSP evaluation and reporting and identify areas for improvement.Data SourcesPubMed, Scopus, and Web of Science.Review MethodsA comprehensive review of the literature published from 2012 through 2024 investigating NSP repair techniques was conducted, and perforation evaluation and outcome reporting were characterized and compared between contemporary and older cohorts.ConclusionsOutcomes of NSP repair are increasingly studied. The heterogeneity of current literature concerning the evaluation of perforations and the reporting of outcomes precludes high‐quality comparative analyses of outcomes across separate studies. This review demonstrated a lack of progress towards greater standardization over the last 12 years. There remains room for improvement in regard to the evaluation and reporting of etiology, defect size, symptomatology, and objective outcome of repair, allowing for adequate duration of follow‐up.Implications for PracticeThere are many inconsistencies in the collection, organization, and analysis of data implicated in investigations of NSP repair outcomes. The development and agreement upon consensus practice guidelines would engender greater standardization among the evaluation and assessment of treatment outcomes. Based on this review and our institutional experiences, we propose specific measures that would facilitate higher‐quality future research and advance the practice of perforation management.

Background Heart failure (HF) is a growing public health burden. Systemic inflammation is commonly observed in patients with HF and believed to be related to disease pathogenesis. Infection is a potential acute trigger of chronic inflammation. Our objective was to examine the relationship between infection‐related hospitalization (IRH) and HF. Methods and Results We studied beneficiaries with at least 15 months of continuous enrollment in the US‐based MarketScan databases during 2013 to 2019. We included n=152 008 patients with an inpatient or outpatient HF International Classification of Diseases, Ninth Revision/Tenth Revision ( ICD‐9/10 ) code in the primary position. Among patients with HF, IRH was identified using select ICD‐9/10 codes. We used a case‐crossover design to compare the frequency of IRH occurring within 3 months of the index HF event (case period) versus the frequency of IRH occurring 12 to 15 months before the index HF event (control period). Logistic models regressed the log‐odds of having an IRH during the case versus control periods; odds ratios (ORs; 95% CIs) are presented. Among 152 008 beneficiaries, 53% were male with a mean±SD age of 56(±11) years. The odds of having an IRH during the case (versus control) period was elevated for both the 3‐month case period (OR, 4.39 [95% CI, 4.18–4.60]), and 1‐month case period (OR, 7.39 [95% CI, 6.88–7.94]), after adjusting for the total number of hospitalizations. This relationship persisted across different types of infections. Conclusions IRH was associated with incident HF after both 1 and 3 months and may represent a modifiable risk factor for HF.